Association of Androgen Hormones, Sex Hormone-Binding Globulin, and the Menopausal Transition With Incident Diabetes Mellitus in Women With and Without HIV.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
15 Apr 2024
15 Apr 2024
Historique:
received:
24
08
2023
accepted:
01
12
2023
medline:
18
3
2024
pubmed:
5
1
2024
entrez:
5
1
2024
Statut:
ppublish
Résumé
HIV is associated with alterations in androgen hormone levels and sex hormone-binding globulin (SHBG) in women. Higher SHBG has been associated with a lower risk of diabetes in the general population, but the contribution of HIV, androgen hormones, SHBG, and menopausal phase to diabetes is unclear. From April 2003 through February 2020, 896 women with HIV (WWH) and 343 women without HIV (WWOH) from the Women's Interagency HIV Study with morning total testosterone, dehydroepiandrosterone sulfate (DHEAS), and SHBG levels were followed to assess for incident diabetes. Parametric regression models were used with age as the time scale and relative times (RT) as the measure of association of hormone level and menopausal phase with incident diabetes. Analyses incorporated time-dependent androgen hormone, SHBG levels, and menopausal phase and were adjusted for race/ethnicity, enrollment year, smoking status, BMI, hepatitis C virus status, and HIV-related factors. In total, 128 (14%) WWH and 47 (14%) WWOH developed diabetes. In WWH, a doubling of SHBG and DHEAS were associated with a 7% (RT = 1.07 [95% CI: 0.82 to 1.40] and 15% (RT = 1.15 [95% CI: 0.95 to 1.39]) longer time to diabetes, respectively; in WWOH, a doubling of SHBG and DHEAS were associated with 84% (RT = 1.84 [95% CI: 0.89 to 3.82]) and 41% (RT= 1.41 [95% CI: 0.82 to 2.44]) longer times to diabetes. Total testosterone was not associated. In WWH, later menopausal phase was associated with shorter times to diabetes. Despite alterations in androgen hormone and SHBG levels in HIV, regardless of HIV status, higher SHBG and DHEAS were associated with nonstatistically significant slower progression to diabetes. The menopausal transition may be a better hormonal indicator of diabetes risk in WWH.
Sections du résumé
BACKGROUND
BACKGROUND
HIV is associated with alterations in androgen hormone levels and sex hormone-binding globulin (SHBG) in women. Higher SHBG has been associated with a lower risk of diabetes in the general population, but the contribution of HIV, androgen hormones, SHBG, and menopausal phase to diabetes is unclear.
METHODS
METHODS
From April 2003 through February 2020, 896 women with HIV (WWH) and 343 women without HIV (WWOH) from the Women's Interagency HIV Study with morning total testosterone, dehydroepiandrosterone sulfate (DHEAS), and SHBG levels were followed to assess for incident diabetes. Parametric regression models were used with age as the time scale and relative times (RT) as the measure of association of hormone level and menopausal phase with incident diabetes. Analyses incorporated time-dependent androgen hormone, SHBG levels, and menopausal phase and were adjusted for race/ethnicity, enrollment year, smoking status, BMI, hepatitis C virus status, and HIV-related factors.
RESULTS
RESULTS
In total, 128 (14%) WWH and 47 (14%) WWOH developed diabetes. In WWH, a doubling of SHBG and DHEAS were associated with a 7% (RT = 1.07 [95% CI: 0.82 to 1.40] and 15% (RT = 1.15 [95% CI: 0.95 to 1.39]) longer time to diabetes, respectively; in WWOH, a doubling of SHBG and DHEAS were associated with 84% (RT = 1.84 [95% CI: 0.89 to 3.82]) and 41% (RT= 1.41 [95% CI: 0.82 to 2.44]) longer times to diabetes. Total testosterone was not associated. In WWH, later menopausal phase was associated with shorter times to diabetes.
CONCLUSIONS
CONCLUSIONS
Despite alterations in androgen hormone and SHBG levels in HIV, regardless of HIV status, higher SHBG and DHEAS were associated with nonstatistically significant slower progression to diabetes. The menopausal transition may be a better hormonal indicator of diabetes risk in WWH.
Identifiants
pubmed: 38180885
doi: 10.1097/QAI.0000000000003380
pii: 00126334-990000000-00360
doi:
Substances chimiques
Androgens
0
Sex Hormone-Binding Globulin
0
Testosterone
3XMK78S47O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
486-493Subventions
Organisme : NHLBI NIH HHS
ID : U01 HL146204
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146242
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01-HL146242
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01-HL146204
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01-HL146245
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01-HL146202
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK 109823
Pays : United States
Organisme : NHLBI NIH HHS
ID : 5K12HL143961-02
Pays : United States
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
P.C.T.: Grant support from Merck. The remaining authors have no conflicts of interest to disclose.
Références
Tien PC, Schneider MF, Cox C, et al. Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr. 2012;61:334–340.
Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS. 2007;21:1739–1745.
Howard AA, Hoover DR, Anastos K, et al. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2010;54:152–159.
Johnston CD, Hoover DR, Shi Q, et al. White blood cell counts, lymphocyte subsets, and incident diabetes mellitus in women living with and without HIV. AIDS Res Hum Retroviruses. 2020;36:131–133.
Glesby MJ, Hanna DB, Hoover DR, et al. Abdominal fat depots, insulin resistance, and incident diabetes mellitus in women with and without HIV infection. AIDS. 2018;32:1643–1650.
Frasco MA, Karim R, Van Den Berg D, et al. Antiretroviral therapy modifies the genetic effect of known type 2 diabetes-associated risk variants in HIV-infected women. AIDS. 2014;28:1815–1823.
Ding EL, Song Y, Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295:1288–1299.
Ding EL, Song Y, Manson JE, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 2009;361:1152–1163.
Brand JS, van der Tweel I, Grobbee DE, et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol. 2011;40:189–207.
Liang J, Peng Q, Yang X, et al. The association between serum testosterone levels and metabolic syndrome among women. Diabetol Metab Syndr. 2021;13:26.
Karim R, Mack WJ, Kono N, et al. Gonadotropin and sex steroid levels in HIV-infected premenopausal women and their association with subclinical atherosclerosis in HIV-infected and -uninfected women in the Women's Interagency HIV Study (WIHS). J Clin Endocrinol Metab. 2013;98:E610–E618.
Burger HG, Dudley EC, Cui J, et al. A Prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab. 2000;85:2832–2838.
Crawford S, Santoro N, Laughlin GA, et al. Circulating dehydroepiandrosterone sulfate concentrations during the menopausal transition. J Clin Endocrinol Metab. 2009;94:2945–2951.
Burger HG. Androgen production in women. Fertil Steril. 2002;77(suppl 4):S3–S5.
Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404–2411.
Donato GB, Fuchs SC, Oppermann K, et al. Association between menopause status and central adiposity measured at different cutoffs of waist circumference and waist-to-hip ratio. Menopause. 2006;13:280–285.
Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4:e124865.
Baglietto L, English DR, Hopper JL, et al. Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat. 2009;115:171–179.
Gruber CJ, Tschugguel W, Schneeberger C, et al. Production and actions of estrogens. N Engl J Med. 2002;346:340–352.
D'Souza G, Bhondoekhan F, Benning L, et al. Characteristics of the MACS/WIHS Combined cohort study: opportunities for research on aging with HIV in the Longest US Observational Study of HIV. Am J Epidemiol. 2021;190:1457–1475.
Adimora AA, Ramirez C, Benning L, et al. Cohort Profile: the Women's Interagency HIV Study (WIHS). Int J Epidemiol. 2018;47:393–394i.
Scherzer R, Greenblatt RM, Merhi ZO, et al. Use of antimüllerian hormone to predict the menopausal transition in HIV-infected women. Am J Obstet Gynecol. 2017;216:46.e1–46.e11.
Freeman EW, Sammel MD, Lin H, et al. Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women. Fertil Steril. 2012;98:1254–1259.e1–2.
Broer SL, Eijkemans MJC, Scheffer GJ, et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab. 2011;96:2532–2539.
Abelman RA, Nguyen TTJ, Ma Y, et al. Body composition changes over the menopausal transition in women with and without Human Immunodeficiency Virus. Clin Infect Dis. 2023;77:265–271.
Harlow SD, Gass M, Hall JE, et al. Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging. The J Clin Endocrinol Metab. 2012;97:1159–1168.
Diagnosis. ADA. Available at: https://diabetes.org/diabetes/a1c/diagnosis . Accessed November 22, 2022.
Cox C, Chu H, Schneider MF, et al. Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution. Stat Med. 2007;26:4352–4374.
Coburn SB, Dionne-Odom J, Alcaide ML, et al. The association between HIV status, estradiol, and sex hormone binding globulin among premenopausal women in the women's interagency HIV study. J Women’s Health. 2022;31:183–193.
Grinspoon S, Corcoran C, Miller K, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab. 1997;82:1332–1337.
Muka T, Nano J, Jaspers L, et al. Associations of steroid sex hormones and sex hormone-binding globulin with the risk of type 2 diabetes in women: a population-based cohort study and meta-analysis. Diabetes. 2017;66:577–586.
Simons PIHG, Valkenburg O, Stehouwer CDA, et al. Sex hormone–binding globulin: biomarker and hepatokine?. Trends Endocrinol Metabol. 2021;32:544–553.
Mather KJ, Kim C, Christophi CA, et al. Steroid sex hormones, sex hormone–binding globulin, and diabetes incidence in the diabetes prevention program. J Clin Endocrinol Metab. 2015;100:3778–3786.
Ding EL, Song Y, Manson JE, et al. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia. 2007;50:2076–2084.
Karim R, Mack WJ, Hodis HN, et al. Influence of age and obesity on serum estradiol, estrone, and sex hormone binding globulin concentrations following oral estrogen administration in postmenopausal women. J Clin Endocrinol Metab. 2009;94:4136–4143.
Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71:1379–1389.
Lake JE, Trevillyan J. Impact of integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV. Curr Opin HIV AIDS. 2021;16:148–151.